Target multiple leukemia gene alterations with one NGS workflow
Accurate and comprehensive molecular profiling is essential
The number of genes that need to be sequenced for blood cancer research has dramatically increased over the past few decades. More, to get accurate results, there must be no compromise on performance, especially when profiling challenging regions.
Current approaches require two separate workflows to prepare libraries from separate DNA and RNA isolates. But analyzing blood cancers with multiple sequencing tests and disparate workflows creates resource inefficiencies and lengthens turnaround times.
A rapid, multimodal NGS solution is a must-have.
DNA and RNA sequencing consolidated into a single workflow
The QIAseq Leukemia Multimodal Panel delivers:
Workflow Benefits |
---|
|
|
Results |
---|
|
|
|
|
|
Other related products
QIAseq Multimodal Pan Cancer Panel
The QIAseq Pan-cancer Multimodal Panel enables simultaneous enrichment and profiling of 605 relevant DNA variant and RNA fusion biomarkers found across multiple cancers, as well as assessment of tumor mutational burden (TMB) and microsatellite instability (MSI), from a single sample input of 10 ng.
QIAseq Targeted DNA Pro Human Myeloid Neoplasms Research Panel
The Human Myeloid Neoplasms Research QIAseq® Targeted DNA Pro Panel is a complete Sample to Insight NGS solution for myeloid neoplasms analysis.
Applying digital RNA sequencing to scan for known and novel fusion genes.
QCI Secondary Analysis is a new cloud-based service for NGS secondary analysis powered by DNAnexus, the world’s most secure and trusted platform for biomedical data analysis.
Connected to the exclusive QIAGEN KnowledgeBase, the industry’s most comprehensive, manually curated resource that is updated weekly, QCI Interpret for QIAseq dynamically computes pathogenicity based on the AMP/ASCO/CAP or ACMG/AMP guidelines for every variant in over 31,000 cancer types with full transparency.